Skip to content

The optimal dose of dexmedetomidine for reduce the postoperative catheter related bladder discomfort in post-anesthesia care unit

The optimal dose of dexmedetomidine for reduce the postoperative catheter related bladder discomfort in post-anesthesia care unit

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220407005
Enrollment
35
Registered
2022-04-07
Start date
2021-09-28
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-related bladder discomfort (CRBD) is defined as an urgent urination or a burning sensation in the suprapubic area. A study showed that 55% of the patients in the post-anesthesia care unit (PACU) experienced moderate or severe CRBD symptoms. CRBD leads to restlessness and agitation and it also enhances the risk of falling out of bed.Moreover, it may increase the workload of nursing staff in the PACU. Therefore, early management of CRBD during anesthesia recovery is clinically significant

Interventions

An anesthesiologist blinded to the dose of dexmedetomidine given to the patients assessed the severity of postoperative CRBD as previously described. Severe CRBD was characterized by the symptom compl
Experimental Drug
Determination of the 90 percent effective dose of dexmedetomidine for treating postoperative catheter related bladder discomfort during recovery

Sponsors

The Quzhou Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists (ASA) I-II patients between 18 and 80 years in the PACU after general anesthesia diagnosed Catheter-related bladder discomfort

Exclusion criteria

Exclusion criteria: Patients with a history of bladder outflow obstruction, urinary tract infection, neurogenic blad-der, chronic analgesic abuse, severe hepatic or renal disease, arrhythmia, and morbid obesity were excluded from this trial.

Design outcomes

Primary

MeasureTime frame
The severity of CRBD 30 min after dexmedetomidine administration Scale to assess

Secondary

MeasureTime frame
adverse effects 30 min after dexmedetomidine administration Major adverse effects of dexmedetomidine including hypotension, hypertension, bradycardia, and sedation were monitored and recorded.

Countries

China

Contacts

Public ContactLiting Ji

The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital

jill23liting@163.com8613587107221

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026